National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Determination 2017 (PB 25 of 2017) (Cth)
National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Determination 2017 (PB 25 of 2017)
made under subsection 99(4) of the
National Health Act 1953
Compilation No. 1
Compilation date: 1 October 2019
Includes amendments up to: PB 57 of 2019
Registered: 19 December 2019
About this compilation
This compilation
This is a compilation of the National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Determination 2017 (PB 25 of 2017) that shows the text of the law as amended and in force on 1 October 2019 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
Part 1—Preliminary 1
1............ Name............................................................................................................................. 1
2A......... Authority....................................................................................................................... 1
2B......... Purpose......................................................................................................................... 1
2D......... Things done under the National Health Act 1953 ‑ Determination under subsection 99(4) (27/10/2006) 1
2E.......... Application and transitional arrangements..................................................................... 1
3............ Definitions..................................................................................................................... 1
Part 2—Rates and conditions of payment—general 4
4............ Amount of payment—amount by which dispensed price exceeds patient co‑payment.. 4
6............ No payment if supply not in accordance with relevant legislation................................. 4
7............ No payment for supply of non‑listed brand................................................................... 4
Part 3—Dispensed price for supply of ready‑prepared pharmaceutical benefits 5
9............ Dispensed price—general.............................................................................................. 5
10.......... Dispensed price—rounding........................................................................................... 5
11.......... Dispensed price—broken quantities.............................................................................. 5
12.......... Dispensed price—price for lesser quantity not to exceed price for greater quantity....... 6
13.......... Dispensed price—pharmaceutical benefits required to be supplied in complete packs.. 6
14.......... Dispensed price—mark‑up on approved ex‑manufacturer price or proportional ex‑manufacturer price 6
Part 4—Dispensed price for supply of extemporaneously‑prepared pharmaceutical benefits 8
Division 1—Calculation method 1 8
18A....... Application of this Division.......................................................................................... 8
18B....... Calculations for certain pharmaceutical benefits............................................................ 8
19.......... Dispensed price—extemporaneously‑prepared pharmaceutical benefits to which this Division applies 8
20.......... Amounts for ingredients—quantity equal to agreed purchase quantity.......................... 9
21.......... Amounts for ingredients—quantity less than agreed purchase quantity........................ 9
22.......... Amounts for ingredients—quantity greater than agreed purchase quantity.................. 11
23.......... Dispensed price—benefit comprising vehicle and additional ingredients.................... 11
24.......... Dispensed price—vehicle is a single liquid ingredient................................................. 11
25.......... Dispensed price—vehicle is a liquid compounded from 2 or more ingredients........... 11
26.......... Rounding—amounts for ingredients........................................................................... 12
28.......... Rounding—basic wholesale prices.............................................................................. 12
33.......... Dispensed price—price for lesser quantity not to exceed price for greater quantity—pharmaceutical benefits 12
34.......... Dispensed price—price for lesser quantity not to exceed price for greater quantity—ingredients of pharmaceutical benefits........................................................................................................................ 12
Division 2—Calculation method 2 13
35A....... Application of this Division........................................................................................ 13
35.......... Dispensed price—extemporaneously‑prepared pharmaceutical benefits to which this Division applies 13
35B....... Rounding—dispensed price for Division 2................................................................. 14
Division 3—Elections by approved hospital authorities relating to calculation methods 15
36.......... Extemporaneously‑prepared pharmaceutical benefits that are not standard formula preparations—general 15
38.......... Extemporaneously‑prepared pharmaceutical benefits that comprise standard formula preparations plus additives 15
39.......... Exceptional benefits..................................................................................................... 15
Schedule 1—Application and transitional arrangements 16
Part 1—Amendments made by the National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Amendment (Budget Measure) Determination 2019 16
1............ Application of amendments......................................................................................... 16
Endnotes17
Endnote 1—About the endnotes 17
Endnote 2—Abbreviation key 18
Endnote 3—Legislation history 19
Endnote 4—Amendment history 20
Part 1—Preliminary
1 Name
(1) This instrument is the National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Determination 2017.
(2) This instrument may also be cited as PB 25 of 2017.
2A Authority
This instrument is made under subsection 99(4) of the National Health Act 1953.
2B Purpose
The purpose of this determination is to determine the amount of the Commonwealth payment for pharmaceutical benefits supplied by an approved hospital authority to a patient receiving treatment in or at a public hospital for which the authority is approved.
2D Things done under the National Health Act 1953 ‑ Determination under subsection 99(4) (27/10/2006)
(1) If:
(a) a thing was done for a particular purpose under the National Health Act 1953 ‑ Determination under subsection 99(4) (27/10/2006) as in force immediately before that Determination was repealed; and
(b) the thing could be done for that purpose under this instrument;
the thing has effect for the purposes of this instrument as if it had been done under this instrument.
(2) Without limiting subsection (1), a reference in that subsection to a thing being done includes a reference to a notice, application or other instrument being given or made.
2E Application and transitional arrangements
Schedule 1 sets out application and transitional arrangements in relation to amendments of this instrument.
3 Definitions
In this instrument:
Act means the National Health Act 1953.
agreed purchase quantity, of an ingredient of an extemporaneously‑prepared pharmaceutical benefit, means the agreed purchase quantity of the ingredient referred to in the determination in force under paragraph 98B(1)(a) of the Act.
approved ex‑manufacturer price has the same meaning as in Part VII of the Act.
approved hospital authority has the same meaning as in Part VII of the Act.
basic wholesale price, in relation to an ingredient of an extemporaneously‑prepared pharmaceutical benefit, is the basic wholesale price of the ingredient referred to in the determination in force under paragraph 98B(1)(a) of the Act.
brand has the same meaning as in Part VII of the Act.
broken quantity, in relation to a ready‑prepared pharmaceutical benefit, means a quantity of the benefit, which is less than a pack quantity.
calculation day means the 16th day of a calendar month or, if the 16th day is not a business day, the next business day.
calculation period, for a calculation day, means the period commencing 4 weeks before the calculation day and ending on the calculation day.
container price, for an extemporaneously‑prepared pharmaceutical benefit, means the price for a container for an extemporaneously‑prepared pharmaceutical benefit calculated in accordance with the determination in force under paragraph 98B(1)(a) of the Act.
determined quantity, of a listed brand of a pharmaceutical item, has the same meaning as in Part VII of the Act.
dispensed price:
(a) for the supply of a ready‑prepared pharmaceutical benefit: see Part 3; and
(b) for the supply of an extemporaneously‑prepared pharmaceutical benefit: see Part 4.
exceptional benefit means an extemporaneously‑prepared pharmaceutical benefit that is not a standard formula preparation and for which the dispensed price calculated under Division 1 of Part 4 (excluding the container price) is at least twice the dispensed price calculated under Division 2 of Part 4 (excluding the container price).
extemporaneously‑prepared pharmaceutical benefit means a pharmaceutical benefit that is not a ready‑prepared pharmaceutical benefit.
listed brand has the same meaning as in Part VII of the Act.
maximum quantity, of a brand of a pharmaceutical item, means a quantity or number of units of the pharmaceutical item determined under paragraph 85A(2)(a) of the Act in relation to that brand of pharmaceutical item.
pack quantity has the same meaning as in Part VII of the Act.
patient co‑payment, for a pharmaceutical benefit, means the charge, if any, that may be made under subsection 87(2) of the Act, to the person to whom the benefit is supplied, by an approved pharmacist or an approved medical practitioner.
pharmaceutical benefit has the same meaning as in Part VII of the Act.
pharmaceutical item has the same meaning as in Part VII of the Act.
proportional ex‑manufacturer price has the same meaning as in Part VII of the Act.
ready‑prepared pharmaceutical benefit means a pharmaceutical benefit in respect of which a determination is in force under subsection 85(6) of the Act.
Regulations means the National Health (Pharmaceutical Benefits) Regulations 2017.
standard formula preparation means a pharmaceutical benefit that is a standard formula preparation under the determination in force under paragraph 98C(1)(b) of the Act.
Note: Under that determination, certain extemporaneously‑prepared pharmaceutical benefits are listed as standard formula preparations.
type, of an extemporaneously‑prepared pharmaceutical benefit that is not a standard formula preparation, means a type of benefit determined under paragraphs 85A(2)(a) and (b) of the Act.
Note: Paragraphs 85A(2)(a) and (b) of the Act provide for the determination of the maximum quantity or number of units of a pharmaceutical benefit that may, in one prescription, be directed to be supplied on any one occasion and the determination of the maximum number of occasions on which the supply of the pharmaceutical benefit may, in one prescription, be directed to be repeated.
vehicle means a substance that has little or no medicinal action and is used as a medium for an active ingredient.
wastage means the combined loss that arises from:
(a) transferring drugs and chemicals from the package in which they are delivered to an approved hospital authority to the dispensing package delivered to a patient; and
(b) deterioration; and
(c) obsolescence.
Part 2—Rates and conditions of payment—general
4 Amount of payment—amount by which dispensed price exceeds patient co‑payment
Subject to sections 6 and 7, the amount payable to an approved hospital authority in respect of the supply of a pharmaceutical benefit to a patient receiving treatment in or at a public hospital in respect of which the approved hospital authority is approved is the amount by which the dispensed price for the supply of the benefit, worked out in accordance with this determination, exceeds the patient co‑payment for the benefit.
6 No payment if supply not in accordance with relevant legislation
A payment will not be made in respect of the supply of a pharmaceutical benefit unless the supply of the benefit was made in accordance with the Act, the Regulations and the relevant determinations made under the Act.
7 No payment for supply of non‑listed brand
Where in respect of a drug or medicinal preparation there is a determination in force under subsection 85(6) of the Act of a brand or brands under which that drug or medicinal preparation may be supplied as a pharmaceutical benefit under Part VII of the Act, no payment by the Commonwealth will be made in respect of the supply by an approved hospital authority of any other brand of that drug or medicinal preparation.
Part 3—Dispensed price for supply of ready‑prepared pharmaceutical benefits
9 Dispensed price—general
Subject to sections 10, 12 and 13, the dispensed price for the supply of a ready‑prepared pharmaceutical benefit is:
(a) if the quantity of the benefit supplied is equal to a multiple of a pack quantity of the benefit—the sum of:
(i) the approved ex‑manufacturer price or the proportional ex‑manufacturer price (as applicable) for each pack quantity; and
(ii) the mark‑up worked out under section 14 for each pack quantity; or
(b) if the quantity of the benefit supplied is a broken quantity—the amount worked out under section 11; or
(c) if the quantity of the benefit supplied is more than a multiple of a pack quantity of the benefit—the sum of:
(i) the approved ex‑manufacturer price or the proportional ex‑manufacturer price (as applicable) for each pack quantity; and
(ii) the mark‑up worked out under section 14 for each pack quantity; and
(iii) the amount worked out under section 11 in respect of the remainder of the quantity supplied that is a broken quantity.
10 Dispensed price—rounding
The amount calculated as the dispensed price for the supply of a ready‑prepared pharmaceutical benefit is rounded to the nearest cent, with one half cent being counted as one cent.
11 Dispensed price—broken quantities
If a broken quantity is supplied, the amount referred to in paragraph 9(b) or subparagraph 9(c)(iii) is worked out using the following method statement.
Method statement
Step 1. Work out the mark‑up on the approved ex‑manufacturer price or proportional ex‑manufacturer price (as applicable) for the pack quantity in accordance with section 14.
Step 2. Add that mark‑up to the approved ex‑manufacturer price or proportional ex‑manufacturer price (as applicable) for the pack quantity.
Step 3. Ascertain the percentage that the broken quantity bears to the pack quantity.
Step 4. Take that percentage of the amount worked out under step 2 (the resulting amount is the dispensed price for the supply of the broken quantity).
12 Dispensed price—price for lesser quantity not to exceed price for greater quantity
Notwithstanding anything contained elsewhere in this instrument, if the dispensed price for the supply of a quantity (the lesser quantity) of a ready‑prepared pharmaceutical benefit would otherwise exceed the dispensed price for a greater quantity of that benefit, the maximum dispensed price for the lesser quantity is reduced to the amount that would be the dispensed price for the greater quantity.
13 Dispensed price—pharmaceutical benefits required to be supplied in complete packs
If a prescription directs the supply of a quantity of a ready‑prepared pharmaceutical benefit that, under the determination in force under paragraph 98C(1)(b) of the Act, is a benefit the complete pack of which will be supplied regardless of any lesser quantity ordered, the dispensed price for the supply of the benefit is the dispensed price of a complete pack.
14 Dispensed price—mark‑up on approved ex‑manufacturer price or proportional ex‑manufacturer price
(1) For the purposes of subparagraphs 9(a)(ii) and (c)(ii) and step 1 in section 11, the mark‑up for a pack quantity of a ready‑prepared pharmaceutical benefit is worked out in accordance with this section.
(2) Work out the relevant quantity for the pack quantity, and the ex‑manufacturer price for the relevant quantity, using the following method statement.
Method statement
Step 1. Identify the approved ex‑manufacturer price (the AEMP) or the proportional ex‑manufacturer price (the PEMP) (as applicable) for the pack quantity.
Step 2. Identify any maximum quantities and any determined quantities of each listed brand of the pharmaceutical item concerned (other than any maximum quantity that relates to a supply of any of those brands that can only be made in accordance with special arrangements under section 100 of the Act).
Step 3. From the quantities identified in step 2, identify the relevant quantity for the pack quantity, which is:
(a) the maximum quantity (if any) that is the highest whole number multiple of the pack quantity, or, if there is no such maximum quantity, the determined quantity (if any) that is the highest whole number multiple of the pack quantity; or
(b) if paragraph (a) does not apply—the maximum quantity (if any) that is the closest to the pack quantity or, if 2 maximum quantities are equally close, the greater of those maximum quantities; or
(c) if paragraph (a) does not apply and there are no maximum quantities—the determined quantity (if any) that is the closest to the pack quantity or, if 2 determined quantities are equally close, the greater of those determined quantities.
Step 4. The ex‑manufacturer price for the relevant quantity is the relevant quantity multiplied by the AEMP or PEMP (as applicable) for the pack quantity.
(3) If the ex‑manufacturer price for the relevant quantity is $930.06 or less, the mark‑up for the pack quantity is 7.52% of the approved ex‑manufacturer price or the proportional ex‑manufacturer price (as applicable) for the pack quantity.
(4) If:
(a) the ex‑manufacturer price for the relevant quantity is more than $930.06; and
(b) the relevant quantity and the pack quantity are the same;
the mark‑up for the pack quantity of the brand of the pharmaceutical item is $69.94.
(5) If:
(a) the ex‑manufacturer price for the relevant quantity is more than $930.06; and
(b) the relevant quantity and the pack quantity are not the same;
the mark‑up for the pack quantity is worked out using the following formula:
Part 4—Dispensed price for supply of extemporaneously‑prepared pharmaceutical benefits
Division 1—Calculation method 1
18A Application of this Division
This Division applies to the supply of an extemporaneously‑prepared pharmaceutical benefit if:
(a) the benefit is a standard formula preparation; or
(b) the benefit is not a standard formula preparation and the approved hospital authority that supplied the benefit has made an election under section 36 in respect of the benefit; or
(c) the pharmaceutical benefit is of a type of benefit included in the determination under paragraphs 85A(2)(a) and (b) of the Act, but for which there is no standard formula preparation listed under the determination in force under paragraph 98C(1)(b) of the Act; or
(d) the benefit comprises a standard formula preparation plus an additive and the approved hospital authority that supplied the benefit has made an election under section 38 in respect of the benefit; or
(e) the benefit is an exceptional benefit and the approved hospital authority that supplied the benefit has made an election under section 39 in respect of the benefit.
18B Calculations for certain pharmaceutical benefits
The dispensed price for a pharmaceutical benefit mentioned in paragraph 18A(d) must be calculated as if the benefit comprised only the standard formula preparation without the additive.
19 Dispensed price—extemporaneously‑prepared pharmaceutical benefits to which this Division applies
The dispensed price for the supply of an extemporaneously‑prepared pharmaceutical benefit to which this Division applies is the sum of:
(a) the price for each quantity of ingredient supplied in the benefit, worked out under sections 20 to 22 (as applicable); and
(b) the container price for the benefit.
20 Amounts for ingredients—quantity equal to agreed purchase quantity
For the purposes of section 19, the amount for a quantity of an ingredient of an extemporaneously‑prepared pharmaceutical benefit, where the quantity of the ingredient is equal to the agreed purchase quantity of the ingredient, is the sum of:
(a) the basic wholesale price of the ingredient, increased by a mark‑up of 10%; and
(b) the wastage factor (if any) referred to in the determination in force under paragraph 98B(1)(a) of the Act, for the agreed purchase quantity of the ingredient.
21 Amounts for ingredients—quantity less than agreed purchase quantity
(1) For the purposes of section 19, the price for a quantity of an ingredient of an extemporaneously‑prepared pharmaceutical benefit, where the quantity of the ingredient is less than the agreed purchase quantity of the ingredient, is worked out using the following method:
Method
| Step 1 | Refer to the table in subsection (3) to identify the basic pricing unit that applies for the quantity of the ingredient. |
| Step 2 | Find the basic pricing unit from Step 1 in column 2 of the table in subsection (4), and then work out the basic wholesale price for the corresponding quantity specified in column 3. Where this quantity is not the agreed purchase quantity, the basic pricing unit will be proportional basic wholesale price. |
| Step 3 | Calculate the cost of the basic pricing unit by applying the corresponding quantity factor calculation in column 4 of the table in subsection (4) to the basic wholesale price from Step 2. |
| Step 4 | If, for the quantity of the ingredient to be supplied, there is a corresponding “price as” quantity specified in column 4 of the table in subsection (3), use the “price as” quantity as the quantity of the ingredient supplied in the benefit for Step 5. |
| Step 5 | Calculate the price for the quantity of the ingredient supplied in the benefit by dividing the quantity of the ingredient, or the “price as” quantity if applicable, by the quantity of the basic pricing unit and multiplying that amount by the cost of the basic pricing unit. |
(2) For the purposes of subsection (1), the quantity of the ingredient will be calculated to the next higher 50 mg or 50 microlitres.
(3) For the purposes of subsection (1), the basic pricing units and “price as” quantities for quantities of ingredients referred to in Steps 1 and 4 of the Method are:
| Basic pricing units for quantities of ingredients | |||
| Item | Quantity | Basic pricing unit | Price as |
| 1 | Up to and including 700 mg | 100 mg | |
| 2 | Up to and including 700 microlitres | 100 microlitres | |
| 3 | More than 700 mg and up to and including 1 g | 1 g | 1 g |
| 4 | More than 700 microlitres and up to and including 1 ml | 1 ml | 1 ml |
| 5 | More than 1 g and up to and including 7 g | 1 g | |
| 6 | More than 1 ml and up to and including 7 ml | 1 ml | |
| 7 | More than 7 g and up to and including 10 g | 10 g | 10 g |
| 8 | More than 7 ml and up to and including 10 ml | 10 ml | 10 ml |
| 9 | More than 10 g and up to and including 80 g | 10 g | |
| 10 | More than 10 ml and up to and including 80 ml | 10 ml | |
| 11 | More than 80 g and up to and including 90 g | 10 g | 80 g |
| 12 | More than 80 ml and up to and including 90 ml | 10 ml | 80 ml |
| 13 | More than 90 g | 100 g | |
| 14 | More than 90 ml | 100 ml | |
(4) For the purposes of subsection (1), the quantities for basic wholesale prices and quantity factor calculations referred to in Steps 2 and 3 of the Method are:
| Quantity factors for basic pricing units | |||
| Item | Basic pricing unit | Quantity for basic wholesale price | Quantity factor calculation: |
| 1 | 100 g | Either: (a) 500 g; or | Either: (a) divide by 5; or (b) divide by 10 |
| 2 | 100 ml | Either: (a) 500 ml; or | Either: (a) divide by 5; or (b) divide by 10 |
| 3 | 10 g | 100 g | Multiply by 1.125, then divide that amount by 10 |
| 4 | 10 ml | 100 ml | Multiply by 1.125, then divide that amount by 10 |
| 5 | 1 g | 10 g | Multiply by 1.25, then divide that amount by 10 |
| 6 | 1 ml | 10 ml | Multiply by 1.25, then divide that amount by 10 |
| 7 | 100 mg | 1 g | Multiply by 1.25, then divide that amount by 10 |
| 8 | 100 microlitres | 1 ml | Multiply by 1.25, then divide that amount by 10 |
22 Amounts for ingredients—quantity greater than agreed purchase quantity
For the purposes of section 19, the amount for a quantity of an ingredient of an extemporaneously‑prepared pharmaceutical benefit, where the quantity of the ingredient is greater than the agreed purchase quantity of the ingredient, is worked out by:
(a) if the ingredient is a drug that is unstable or packed sterile under the determination in force under paragraph 98C(1)(b) of the Act—multiplying the price of the agreed purchase quantity of the ingredient by the number of whole packs of the agreed purchase quantity of the ingredient that are required to dispense the quantity of the ingredient; or
(b) in any other case—dividing the quantity of the ingredient to be dispensed by the agreed purchase quantity of the ingredient and multiplying the resultant amount by the basic wholesale price of the agreed purchase quantity of the ingredient.
23 Dispensed price—benefit comprising vehicle and additional ingredients
The dispensed price for the supply of an extemporaneously‑prepared pharmaceutical benefit which comprises:
(a) a vehicle which is specified in the prescription under a particular name; and
(b) an additional specified ingredient or ingredients;
must be calculated under section 24 or 25 (as applicable).
24 Dispensed price—vehicle is a single liquid ingredient
If the vehicle is a single liquid ingredient and one or more other ingredients are added, any displacement of the vehicle by solids must be disregarded for pricing purposes and the dispensed price for the supply of the benefit as a whole must be calculated under section 19.
25 Dispensed price—vehicle is a liquid compounded from 2 or more ingredients
In calculating the dispensed price for a benefit where the vehicle is a liquid compounded from 2 or more ingredients and one or more other ingredients are added:
(a) any displacement of the vehicle by solids is disregarded; and
(b) the price for the ingredients is the sum of:
(i) the price of each ingredient of the vehicle; and
(ii) the price of each ingredient which is added to the vehicle;
calculated in each case under section 19.
26 Rounding—amounts for ingredients
The amount worked out for an ingredient under section 19 is rounded to the nearest cent, one half cent being counted as one cent, provided that the minimum amount in respect of an ingredient is one cent.
28 Rounding—basic wholesale prices
The basic wholesale price for an approved purchase quantity of an ingredient is rounded to the nearest cent, one half cent being counted as one cent, provided that the minimum amount in respect of an ingredient is one cent.
33 Dispensed price—price for lesser quantity not to exceed price for greater quantity—pharmaceutical benefits
Notwithstanding anything contained elsewhere in this instrument, if the dispensed price for the supply of a quantity (the lesser quantity) of an extemporaneously‑prepared pharmaceutical benefit would otherwise exceed the dispensed price for the supply of a greater quantity of that benefit, the maximum dispensed price for the lesser quantity is reduced to the amount that would be the dispensed price for the greater quantity.
34 Dispensed price—price for lesser quantity not to exceed price for greater quantity—ingredients of pharmaceutical benefits
Notwithstanding anything contained elsewhere in this instrument, if the dispensed price for the supply of a quantity (the lesser quantity) of an ingredient of an extemporaneously‑prepared pharmaceutical benefit would otherwise exceed the dispensed price for a greater quantity of that ingredient, the maximum dispensed price for the lesser quantity is reduced to the amount that would be the dispensed price for the greater quantity.
Division 2—Calculation method 2
35A Application of this Division
This Division applies to the supply of an extemporaneously‑prepared pharmaceutical benefit to which Division 1 does not apply.
35 Dispensed price—extemporaneously‑prepared pharmaceutical benefits to which this Division applies
(1) The dispensed price for the supply of an extemporaneously‑prepared pharmaceutical benefit to which this Division applies is worked out using the following method:
Method
| Step 1 | On the calculation day, ascertain: (a) the total quantity of the type of extemporaneously‑prepared pharmaceutical benefit, in grams or millilitres as the case may be, which is the same type of benefit as the benefit to be supplied; and (b) the total cost (excluding container price) of the total quantity of that type of benefit; that has been supplied during the calculation period. |
| Step 2 | Divide the total cost (excluding the container price) by one‑tenth of the total number of grams or millilitres, to work out the average 10 grams or 10 millilitres unit cost for the type of benefit. |
| Step 3 | Multiply the average 10 grams or 10 millilitres unit cost calculated in Step 2 by one‑tenth of the quantity to be supplied in g or ml. |
| Step 4 | Add the container price to the amount calculated in Step 3. |
(2) If no standard formula preparation of a type of benefit has been supplied during the calculation period, and therefore a reliable average cost for the calculation period cannot be obtained using the method in subsection (1), the dispensed price is worked out using the following method:
Method
| Step 1 | On the calculation day: Add together the price (excluding container price) of each standard formula preparation available for the type of benefit. |
| Step 2 | Calculate the average 10 g or 10 ml rate for the type of benefit by dividing the total price (excluding container price) by one‑tenth of the total number of g or ml in the standard formula preparations used in Step 1. |
| Step 3 | Multiply the average 10 g or 10 ml rate by one‑tenth of the quantity to be supplied in g or ml. |
| Step 4 | Add the container price to the amount calculated in Step 3. |
35B Rounding—dispensed price for Division 2
The dispensed price worked out under section 35 is rounded to the nearest cent, one half cent being counted as one cent.
Division 3—Elections by approved hospital authorities relating to calculation methods
36 Extemporaneously‑prepared pharmaceutical benefits that are not standard formula preparations—general
An approved hospital authority may elect that the dispensed prices for the supply of extemporaneously‑prepared pharmaceutical benefits that are not standard formula preparations are to be calculated under Division 1, instead of under section 35.
38 Extemporaneously‑prepared pharmaceutical benefits that comprise standard formula preparations plus additives
If an extemporaneously‑prepared pharmaceutical benefit comprises a standard formula preparation plus an additive, and the approved hospital authority has not elected under section 36 to calculate the dispensed price of the benefit under Division 1, the dispensed price is calculated under Division 2, unless the approved hospital authority indicates that the benefit is to be priced under Division 1, as if it were a standard formula preparation without the additive.
39 Exceptional benefits
An approved hospital authority may elect that the dispensed price for an exceptional benefit is to be calculated under Division 1.
Schedule 1—Application and transitional arrangements
Note: See section 2E.
Part 1—Amendments made by the National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Amendment (Budget Measure) Determination 2019
1 Application of amendments
The amendments of Part 3 of this instrument by the National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Amendment (Budget Measure) Determination 2019 apply in relation to the supply of a pharmaceutical benefit on or after 1 October 2019.
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = Legislation Act 2003 | Sch = Schedule(s) |
| LIA = Legislative Instruments Act 2003 | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |
Endnote 3—Legislation history
| Name | Registration | Commencement | Application, saving and transitional provisions |
| National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Determination 2017 (PB 25 of 2017) | 31 Mar 2017 (F2017L00372) | 1 Apr 2017 (s 2(1) item 1) | |
| National Health (Commonwealth Price—Pharmaceutical Benefits Supplied By Public Hospitals) Amendment (Budget Measure) Determination 2019 (PB 57 of 2019) | 1 July 2019 (F2019L00940) | 1 Oct 2019 (s 2(1) item 1) | — |
Endnote 4—Amendment history
| Provision affected | How affected |
| Part 1 | |
| s 2............................................. | rep LA s 48D |
| s 2C.......................................... | rep LA s 48C |
| s 2E.......................................... | ad F2019L00940 |
| s 3............................................. | am F2019L00940 |
| Part 3 | |
| s 9............................................. | am F2019L00940 |
| s 11........................................... | rs F2019L00940 |
| s 14........................................... | ad F2019L00940 |
| Schedule 1 | |
| Schedule 1................................ | rep LA s 48C |
| ad F2019L00940 |
0
0
0